Prostate Cancer - Results from #280

Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. November 4, 2024

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. November 4, 2024

The TALAPRO-3 study design: a plain language summary. November 4, 2024

Black men's experiences of support following treatment for prostate cancer in England: A qualitative study. November 4, 2024

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer. November 4, 2024

The Use of Novel Instrumented Socks to Detect Changes in Daily Life Mobility During an Exercise Intervention in Prostate Cancer Survivors Treated with Androgen Deprivation Therapy. November 4, 2024

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer November 1, 2024

Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. November 1, 2024

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. November 1, 2024

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. November 1, 2024

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617. November 1, 2024

PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. November 1, 2024

Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database. October 31, 2024

Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study. October 31, 2024

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC) October 31, 2024

Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. October 31, 2024

A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing. October 31, 2024

The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development October 30, 2024

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. October 30, 2024

AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer. October 30, 2024

Page 15 of 1449